ScreenerHero
CYTKCytokinetics, Incorporated
NAS · US · Healthcare · Biotechnology · cytokinetics.com
77.33USD-0.53%Mkt Cap: 10.81B $P/E: —

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the Unit…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap10.81B $
Enterprise Value10.99B $
Revenue (TTM)67.67M $
Gross Profit-327.99M $
Net Income (TTM)-784.96M $
Revenue/Share0.5440 USD
Last Price77.33 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees673
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.34
PEG—
EV/EBITDA-15.80
EV/Revenue162.39
P/S158.56
P/B-61.74
EPS (TTM)-7.18
EPS (Forward)-4.45
52W Range
35.2279% of range88.31
52W High88.31 USD
52W Low35.22 USD
Profitability
Gross Margin-372.55%
Oper. Margin-625.95%
EBITDA Margin0.00%
Profit Margin-891.60%
ROE119.00%
ROA-55.10%
Growth
Revenue Growth-57.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-510.01M $
CapEx (TTM)24.81M $
FCF Margin-587.27%
FCF Yield-3.68%
Net Debt258.77M $
Net Debt/EBITDA-0.37
Balance Sheet
Debt/Equity-1.95
Current Ratio6.66
Quick Ratio6.56
Book Value/Sh-1.2500 USD
Cash/Share8.385 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJun 25, 2013
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)109.90 USD
Upside (mean)+42.1%
Target Range85.00 USD – 146.00 USD
$85.00+42.1% to mean$146.00
# Analysts20
Ownership
Shares Out.139.02M
Float138.39M
Insiders0.65%
Institutions125.75%
Short Interest
Short Ratio8.6d
Short % Float16.85%
Short % Out.11.03%
Shares Short15.30M
Short (prev mo.)17.57M
Technical
SMA 5079.38 (-2.6%)
SMA 20069.12 (+11.9%)
Beta0.38
S&P 52W Chg18.16%
Avg Vol (30d)1.72M
Avg Vol (10d)1.91M
Technical Indicators
RSI (14)49.1
MACD-1.1583
MACD Signal-0.8892
MACD Hist.-0.2691
BB Upper83.22 USD
BB Middle78.18 USD
BB Lower73.15 USD
BB Width12.88%
ATR (14)2.831 USD
Vol Ratio (20d)0.82x